

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

DEC 29 2005

Applicants	:	Jennings et al.	)	Examiner:
Serial No.	:	10/619,323	)	Maher M. Haddad
Cnfrm. No.	:	8249	)	Art Unit:
Filed	:	July 14, 2003	)	1644
For	:	METHODS OF MODIFYING BEHAVIOR OF	)	
		CD9-EXPRESSING CELLS	)	

**RESPONSE TO RESTRICTION REQUIREMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the September 29, 2005, written restriction requirement, applicants hereby elect Group 47 (i.e. claims 72-75) with traverse. Applicants traverse the restriction in its entirety, because the product and process claims can be searched without undue burden. For this reason, the written restriction requirement is improper and, therefore, applicants respectfully request that the written restriction requirement be withdrawn in its entirety.

In response to the election of species requirement, applicants hereby elect with traverse the polypeptide fragments of CD9 comprising SEQ ID NO: 3, which is generic to SEQ ID NOS: 4-6. Claims readable upon the elected species (subgenus, actually) include claims 72-75. Applicants traverse the election of species requirement, because both the subgenus and the three species can be searched and examined without undue burden.

Respectfully submitted,

Date: December 29, 2005

Edwin V. Merkel  
Edwin V. Merkel  
Registration No. 40,087

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600

CERTIFICATE OF TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO at (571) 273-8300, on December 29, 2005.	
<u>December 29, 2005</u>	<u>Edwin V. Merkel</u> Edwin V. Merkel